Figure 1From: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensOverall survival (OS) and progression free survival (PFS) in all enrolled patients. The OS (A) and PFS (B) were analyzed by the Kaplan-Meier method. OS was measured in days from the 1st vaccination to death and the PFS were measured in days from the1st vaccination to disease progression.Back to article page